Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.
Kadri AltundağTaner BabacanOrhan EfeAhmet S. HasırcıFatih DemirciHakan BüyükhatipoğluOzan BalakanFurkan SariciNeyran KertmenEce EsinSerkan AkınÖztürk AteşSercan AksoyAli Sever
1
Citation
0
Reference
10
Related Paper
Citation Trend
Abstract:
e12035 Background: Capecitabine is a potent and safe agent, which can be used after antracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of capecitabine monotherapy as a first-line treatment in HER-2 negative MBC patients. Methods: In this single center trial, a total of 109 HER-2 negative MBC patients who received capecitabine monotherapy in the first-line treatment between 2003 and 2014 were retrospectively analyzed.Kaplan Meier survival analysis was carried out for progression free survival (PFS) and for overall survival (OS). Two-sided p values of < 0.05 were considered as statistically significant. Results: Median PFS was 7.0 ±0.67 (CI: 5.6-8.3) months and median OS was 30 ±4.1 (CI: 21.8-38.1) months. First-line capecitabine treatment for HER-2 negative MBC was more effective in ER positive patient population compared to ER negative group (median PFS: 9 vs. 4 months (p = 0.002), median OS: 33 vs. 21 months (p = 0.01). Indeed, the overall response rate in ER negative group was 16%, while this was calculated as 38% for ER positive cases. While most of our patient population was treated with a higher dose (1250 mg/m2), the observed grade 3-4 toxicities were lower compared to some previously reported phase II and phase III capecitabine studies. Conclusions: Capecitabine monotherapy is an effective and safe regimen for ER positive, HER-2 negative MBC patients. Its low toxicity profile compared to other intravenous cytotoxic agents and the ease of its oral administration make this agent a preferable option for both physicians and patients.Keywords:
Taxane
Regimen
Progression-free survival
Objective To evaluate the efficacy and toxicity of the combination of capecitabine and gemcitabine as second-line treatment of anthracycline and(or) taxol resistant metastatic breast cancer patients.Methods Patients with metastatic breast cancer were treated with capecitabine 2000mg/m2/d orally bid on day 1~14 and gemcitabine 1000 mg/m2 IV on days 1 and 8 and repeated for 21 days.Results Complete remission was 3/34(8.82%) and partial remission was 12/34(35.29%).Stable disease was 11/34(32.35%) and progressive disease was 8/34(23.53%).Conclusion Combination of capecitabine and gemcitabine is an active and safe regimen as second-line therapy for anthracycline and(or) taxol resistant metastatic breast cancer.It can be a salvage treatment option for anthracycline and(or) taxo1 resistant metastatic breast cancer patients.
Regimen
Cite
Citations (0)
Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer. We compared the efficacy and safety of capecitabine monotherapy between 1st, 2nd, 3rd and > or =4th line settings for advanced and metastatic breast cancer pre-treated with/without anthracycline and taxanes.Subjects comprised 84 patients with histologically confirmed advanced or metastatic breast cancer and at least one measurable metastatic lesion. We evaluated time to disease progression (TTP), response rate (RR) and clinical benefit rate (CBR) for 1st (n = 17), 2nd (n = 28), 3rd (n = 23) and > or =4th (n = 16) line setting treatments of capecitabine monotherapy.Median number of cycles of capecitabine monotherapy was 12 cycles in 1st line, 11 cycles in 2nd line, 9 cycles in 3rd line and 11 cycles in > or =4th line. RR and CBR were 23.5% and 58.8% in 1st line, 21.4% and 53.6% in 2nd line, 21.7% and 52.2% in 3rd line, and 18.8% and 50.0% in > or =4th line, respectively. No significant differences in TTP were seen between each line setting (P = 0.843).Capecitabine monotherapy is effective and well tolerated in all line settings of chemotherapy in patients with metastatic or advanced breast cancer, and is suitable for outpatient therapy.
Taxane
Cite
Citations (4)
Cite
Citations (0)
Cite
Citations (0)
Taxane
Adjuvant Therapy
Cite
Citations (14)
Cite
Citations (11)
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The objective of this review is to compare taxane containing adjuvant chemotherapy regimens with adjuvant regimens not containing a taxane in the management of women with operable breast cancer. Regimens include: Regimen A plus taxane vs Regimen A Regimen A plus taxane vs Regimen B Regimen A with taxane substituted for one or more drugs vs Regimen A
Taxane
Regimen
Cite
Citations (2)
The review analyzed the role of capecitabine and eribulin in the treatment of HER2-negative metastatic breast cancer in patients pretreated with anthracyclines and taxanes. The mechanism of the antitumor action of capecitabine and eribulin, the efficacy in various biological subtypes of breast cancer and safety of treatment is described. The results of a comparative analysis of the efficacy and safety of eribulin monotherapy compared with capecitabine therapy as a second-line treatment for advanced HER2-negative breast cancer are presented.
Eribulin
Cite
Citations (2)
Purpose:To study the efficiency and safety on vinorelbine combined with capecitabine in the treatment of metastatic breast cancer. Methods:Twenty-eight patients with measurable lesions of metestetic breast cancer received vinorelbine 6 mg/m 2 d 1-5 civ,cycles were repeated every 21 days. Patients received capecitabine for 2-4 cycles at the same time. All patients received more than one course of chemotherapy regimens and 19 patients had adriamycin and (or) paclitaxel treatment. Results:Thirteen patients received two cycles treatment and fifteen patients received four cycles of treatment. Complete response in one patient,partial response in six patients,minor response in seven patients,stable response in seven patients and progressive disease in seven patients were observed. Overall responsed rate was 50%.The common side effects were neutronpenia,hand-foot syndrome,skin pigmentation,fatigue. Conclusions:The combination of vinorelbine and capecitabine in the treatment of metastatic breast cancer was effective and the toxicities were tolerable. It is possible that this regimen is an ideal second line chemotherapy for metastatic breast cancer.
Vinorelbine
Regimen
Cite
Citations (1)